Literature DB >> 22383046

Improving psychotherapeutic medication prescribing in Florida: implementation of the Florida Medicaid Drug Therapy Management Program (MDTMP).

Robert J Constantine1, Marie A McPherson, Mary Elizabeth Jones, Rajiv Tandon, Edmund R Becker.   

Abstract

This paper describes a program that was established by Florida Medicaid to improve the quality of prescribing of psychotherapeutic medications. It relates the process used for defining quality medication treatment including the definitions of unusual psychotherapeutic medication indicators (UPMI). It details the results of analysis of FY 2007-2008 pharmacy claims data using these indicators that enabled the Program to identify practices and prescribers that required targeted interventions. The most frequently triggered UPMI for adults involved the use of 2 or more antipsychotics for greater than 60 days; high doses of psychotherapeutic medications was the indicator most frequently triggered for children closely followed by the use of 2 or more antipsychotics for more than 45 days. Prescriptions that triggered UPMI were concentrated in a small number of prescribers. These results led to the Program focusing on these high frequency practices and on the prescribers most associated with them. They also led to the implementation of new quality improvement initiatives like the implementation of a psychiatric telephone consultation line for pediatricians who are treating children with serious emotional disturbances who do not have access to child psychiatrists.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22383046     DOI: 10.1007/s10597-012-9497-y

Source DB:  PubMed          Journal:  Community Ment Health J        ISSN: 0010-3853


  40 in total

Review 1.  Applying theory-driven approaches to understanding and modifying clinicians' behavior: what do we know?

Authors:  Matthew B Perkins; Peter S Jensen; James Jaccard; Peter Gollwitzer; Gabriele Oettingen; Elizabeth Pappadopulos; Kimberly E Hoagwood
Journal:  Psychiatr Serv       Date:  2007-03       Impact factor: 3.084

2.  Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004.

Authors:  Todd P Gilmer; Christian R Dolder; David P Folsom; William Mastin; Dilip V Jeste
Journal:  Psychiatr Serv       Date:  2007-07       Impact factor: 3.084

3.  Enrollment is driving Medicaid costs--but two targets can yield savings.

Authors:  John Holahan; Alshadye Yemane
Journal:  Health Aff (Millwood)       Date:  2009 Sep-Oct       Impact factor: 6.301

4.  The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms.

Authors:  A L Miller; J A Chiles; J K Chiles; M L Crismon; A J Rush; S P Shon
Journal:  J Clin Psychiatry       Date:  1999-10       Impact factor: 4.384

5.  The Cochrane Collaboration. Preparing, maintaining, and disseminating systematic reviews of the effects of health care.

Authors:  L Bero; D Rennie
Journal:  JAMA       Date:  1995-12-27       Impact factor: 56.272

6.  Physician involvement in quality assurance.

Authors:  L S Sommers; R Sholtz; R M Shepherd; D B Starkweather
Journal:  Med Care       Date:  1984-12       Impact factor: 2.983

7.  A multisite randomized trial of the effects of physician education and organizational change in chronic asthma care: cost-effectiveness analysis of the Pediatric Asthma Care Patient Outcomes Research Team II (PAC-PORT II).

Authors:  Sean D Sullivan; Todd A Lee; David K Blough; Jonathan A Finkelstein; Paula Lozano; Thomas S Inui; Anne L Fuhlbrigge; Vincent J Carey; Ed Wagner; Kevin B Weiss
Journal:  Arch Pediatr Adolesc Med       Date:  2005-05

8.  Reducing antibiotic use for acute bronchitis in primary care: blinded, randomised controlled trial of patient information leaflet.

Authors:  John Macfarlane; William Holmes; Philip Gard; David Thornhill; Rosamund Macfarlane; Richard Hubbard
Journal:  BMJ       Date:  2002-01-12

9.  The Texas medication algorithm project: clinical results for schizophrenia.

Authors:  Alexander L Miller; M Lynn Crismon; A John Rush; John Chiles; T Michael Kashner; Marcia Toprac; Thomas Carmody; Melanie Biggs; Kathy Shores-Wilson; Judith Chiles; Brad Witte; Christine Bow-Thomas; Dawn I Velligan; Madhukar Trivedi; Trisha Suppes; Steven Shon
Journal:  Schizophr Bull       Date:  2004       Impact factor: 9.306

10.  Effects of a limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia.

Authors:  S B Soumerai; T J McLaughlin; D Ross-Degnan; C S Casteris; P Bollini
Journal:  N Engl J Med       Date:  1994-09-08       Impact factor: 91.245

View more
  3 in total

1.  Polypharmacy in attention deficit hyperactivity disorder treatment: current status, challenges and next steps.

Authors:  Regina Bussing; Almut G Winterstein
Journal:  Curr Psychiatry Rep       Date:  2012-10       Impact factor: 5.285

2.  Identifying potential prescribing safety indicators related to mental health disorders and medications: A systematic review.

Authors:  Wael Y Khawagi; Douglas T Steinke; Joanne Nguyen; Richard N Keers
Journal:  PLoS One       Date:  2019-05-24       Impact factor: 3.240

3.  Development of a Symptom-Focused Model to Guide the Prescribing of Antipsychotics in Children and Adolescents: Results of the First Phase of the Safer Use of Antipsychotics in Youth (SUAY) Clinical Trial.

Authors:  Robert B Penfold; Ella E Thompson; Robert J Hilt; Nadine Schwartz; Adelaide S Robb; Christoph U Correll; Douglas Newton; Kelly Rogalski; Marian F Earls; Robert A Kowatch; Arne Beck; Bobbi Jo H Yarborough; Stephen Crystal; Benedetto Vitiello; Kelly J Kelleher; Gregory E Simon
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2021-05-04       Impact factor: 8.829

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.